LEXX Insider Trading
Insider Ownership Percentage: 26.40%
Insider Buying (Last 12 Months): $49,063.18
Insider Selling (Last 12 Months): $0.00
Lexaria Bioscience Share Price & Price History
Current Price: $1.12
Price Change: ▲ Price Increase of +0.01 (0.90%)
As of 12/4/2025 05:00 PM ET
Lexaria Bioscience Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/30/2025 | Christopher Bunka | Director | Buy | 11,900 | $0.91 | $10,829.00 | 281,912 |  |
| 7/29/2025 | Christopher Bunka | Director | Buy | 15,600 | $0.92 | $14,352.00 | 270,012 | |
| 7/29/2025 | John Martin Docherty | Insider | Buy | 5,376 | $0.93 | $4,999.68 | 5,376 | |
| 7/29/2025 | Richard Christopher | CEO | Buy | 15,000 | $0.91 | $13,650.00 | 65,000 | |
| 7/29/2025 | Vanessa Carle | Insider | Buy | 750 | $0.91 | $682.50 | 750 | |
| 7/29/2025 | William Edward Mckechnie | Director | Buy | 5,000 | $0.91 | $4,550.00 | 18,191 | |
| 12/2/2024 | Richard Christopher | CEO | Buy | 22,828 | $2.24 | $51,134.72 | 22,828 | |
| 8/12/2024 | Catherine C Turkel | Director | Buy | 1,600 | $3.13 | $5,008.00 | 3,100 | |
| 7/31/2024 | Vanessa Carle | insider | Sell | 2,567 | $4.00 | $10,268.00 | | |
| 2/9/2023 | Catherine C Turkel | Director | Buy | 1,500 | $2.84 | $4,260.00 | 1,500 | |
Lexaria Bioscience Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/17/2025 | Invenomic Capital Management LP | 477,201 | $0.46M | 0.0% | -4.8% | 2.147% |  |
| 11/14/2025 | Virtu Financial LLC | 29,360 | $28K | 0.0% | N/A | 0.132% | |
| 5/16/2025 | Invenomic Capital Management LP | 549,947 | $0.94M | 0.0% | +33.9% | 3.132% | |
| 4/16/2025 | Byrne Asset Management LLC | 28,905 | $49K | 0.0% | +122.3% | 0.165% | |
| 3/17/2025 | Wealth Enhancement Advisory Services LLC | 28,873 | $61K | 0.0% | +108.9% | 0.164% | |
| 2/17/2025 | Invenomic Capital Management LP | 410,731 | $0.86M | 0.0% | -13.7% | 2.340% | |
| 2/13/2025 | Raymond James Financial Inc. | 60,640 | $0.13M | 0.0% | N/A | 0.346% | |
| 2/12/2025 | Geode Capital Management LLC | 166,679 | $0.35M | 0.0% | +10.8% | 0.950% | |
| 2/7/2025 | HighTower Advisors LLC | 21,023 | $44K | 0.0% | +61.4% | 0.120% | |
| 2/6/2025 | Raymond James Financial Inc. | 60,640 | $0.13M | 0.0% | N/A | 0.346% | |
| 1/28/2025 | Byrne Asset Management LLC | 13,000 | $27K | 0.0% | +132.1% | 0.074% | |
| 11/16/2024 | Geode Capital Management LLC | 150,391 | $0.46M | 0.0% | +31.0% | 0.951% | |
| 11/15/2024 | XTX Topco Ltd | 18,626 | $57K | 0.0% | +47.8% | 0.118% | |
| 11/15/2024 | Invenomic Capital Management LP | 475,773 | $1.45M | 0.1% | -7.4% | 3.007% | |
| 11/15/2024 | HighTower Advisors LLC | 13,023 | $40K | 0.0% | N/A | 0.082% | |
| 8/15/2024 | Armistice Capital LLC | 1,020,000 | $2.84M | 0.0% | N/A | 7.916% | |
| 8/9/2024 | Renaissance Technologies LLC | 22,800 | $63K | 0.0% | N/A | 0.177% | |
| 5/16/2024 | Invenomic Capital Management LP | 473,265 | $1.72M | 0.1% | -35.3% | 3.672% | |
| 4/9/2024 | Welch Group LLC | 24,000 | $87K | 0.0% | N/A | 0.194% | |
| 2/14/2024 | Invenomic Capital Management LP | 731,981 | $0.92M | 0.0% | -4.2% | 7.011% | |
| 2/8/2024 | Cowen AND Company LLC | 256,327 | $0.32M | 0.1% | N/A | 2.455% | |
| 11/15/2023 | Armistice Capital LLC | 889,272 | $0.89M | 0.0% | N/A | 10.992% | |
| 8/14/2023 | Invenomic Capital Management LP | 766,573 | $0.56M | 0.0% | +62.0% | 9.476% | |
| 8/8/2022 | Merit Financial Group LLC | 21,267 | $63K | 0.0% | N/A | 0.357% | |
| 2/11/2022 | Invenomic Capital Management LP | 359,113 | $1.45M | 0.3% | +1.9% | 6.034% | |
| 11/15/2021 | MD Financial Management Inc. | 407,687 | $2.55M | 0.1% | +15,078.2% | 7.988% | |
Data available starting January 2016
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Read More on Lexaria Bioscience
Volume
212,378 shs
Average Volume
136,065 shs
Market Capitalization
$24.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.63
Who are the company insiders with the largest holdings of Lexaria Bioscience?
Who are the major institutional investors of Lexaria Bioscience?
Which institutional investors are selling Lexaria Bioscience stock?
During the previous quarter, LEXX stock was sold by these institutional investors:
- Invenomic Capital Management LP
Which institutional investors are buying Lexaria Bioscience stock?
Within the last quarter, LEXX stock was purchased by institutional investors including:
- Virtu Financial LLC
In the previous year, these company insiders have bought Lexaria Bioscience stock:
- Christopher Bunka (Director)
- Richard Christopher (CEO)
- William Edward Mckechnie (Director)
- John Martin Docherty (Insider)
- Catherine C Turkel (Director)
- Vanessa Carle (Insider)
Learn More investors buying Lexaria Bioscience stock.
